ANN ARBOR — A new test that detects asymptomatic individuals who may be at risk for cardiovascular disease is being launched in Europe at the Healthcare Innovation Expo 2013.
The device, known as AngioDefender, was developed by Everist Genomics Inc. of Ann Arbor in collaboration with scientists at Rutgers University in New Jersey. The developers claim that the test will lower the cost of detecting and treating cardiovascular problems and improve patient outcomes.
The test is non-invasive, takes 15 minutes and uses an arm cuff much like a blood pressure test. However, this test can detect signs of early onset cardiovascular disease. It measures the functional health of endothelial cells in the brachial artery of the arm which independent research has shown to be a very reliable indicator of cardiovascular health.
“We have received approval to add the CE mark to our novel medical device,” says Steve Everist, CEO of Everist Genomics. “The CE mark opens up the market for this device to countries in the European Union and to other countries that recognize the CE mark. Use of the test will help to save lives through the early detection of cardiovascular disease, particularly in asymptomatic individuals, i.e., young people who are fit, non-smokers and have no family history of heart problems. At the same time, because early detection of potential heart problems has the ability to reduce health care costs, we believe this test will appeal to government and private health care providers. Heart disease is the biggest single killer of both men and women in Europe, North America, and elsewhere in the world.”
Everist Genomics is introducing the AngioDefender at the Healthcare Innovation Expo 2013, where it hopes to meet potential UK partners in both the government and private sector. Following its UK introduction, the company also expects to seek distributors for its technology throughout the European Union.
“We chose to launch the AngioDefender at the NHS Healthcare Innovation Expo because we believe the Expo provides the best possible showcase for a novel device that can both lower health costs and improve patient outcomes,” Everist said.
The NHS Healthcare Innovation Expo will be held at ExCeL London Convention Centre, located at the London Royal Docks. Everist Genomics, Inc. will be located at Stand D-02.
Everist Genomics develops and commercializes diagnostics, prognostics and therapeutic selection technologies. EGI is focused on rapidly growing disease areas with major unmet needs, including cancer, cardiovascular disease and metabolic diseases such as diabetes. EGI’s products integrate with mobile digital services, smartphones and tablet computers resulting in advanced medical technology which, until now, has been confined to the hospital setting.
More at www.everistgenomics.com.